Advisory Board August 27, 2024
Johnson & Johnson (J&J) last week announced that it planned to change 340B pricing for its two most popular drugs, Stelara and Xarelto. However, hospital groups and the federal government have pushed back on the decision.
Cheat sheet: 340B Drug Pricing Program
J&J announces changes to 340B pricing for 2 of its drugs
The 340B program was launched in 1992 to help hospitals and clinics provide care for low-income and rural patients. Through the program, drug companies that participate in Medicare or Medicaid must offer their medications at a discount to participating hospitals.
The program has grown significantly since it was first launched, and there are now around 55,000 participating entities. In 2023, discounted 340B prices reached $124 billion, a...
Today's Sponsors
Today's Sponsor